Skip to main content
Top
Published in: BMC Public Health 1/2019

Open Access 01-12-2019 | Human Immunodeficiency Virus | Research article

Perceived risk versus objectively measured risk of HIV acquisition: a cross-sectional study among HIV-negative individuals in Serodiscordant partnerships with clients attending an Urban Clinic in Uganda

Authors: Lillian Tugume, Timothy Ronald Muwonge, Edith Nakku Joloba, John Bosco Isunju, Flavia Matovu Kiweewa

Published in: BMC Public Health | Issue 1/2019

Login to get access

Abstract

Background

Acceptability of Pre-exposure Prophylaxis (PrEP) could be hampered by low self-perceived risk for HIV acquisition. Moreover, discordance between risk perception and actual risk of HIV acquisition is likely to occur. We assessed congruence between the level of self- perceived and that of objectively scored risk of HIV acquisition among HIV-negative individuals in discordant relationships.

Methods

This was a cross-sectional study among a representative sample of HIV-negative adult males and females whose partners were receiving antiretroviral therapy for at least 3 months from the Infectious Diseases Institute Clinic in Kampala, Uganda. Perceived risk was measured based on self-report using a numerical rating scale whereas objective risk was measured using a validated risk score tool. Congruence between perceived risk and objectively scored risk was evaluated using descriptive statistics and validity measures. Incongruence between the two phenomena was further evaluated using univariate and multivariate regression analyses.

Results

HIV-negative partners evaluated in this study were mostly male (64%) with a median age of 41 years (IQR 35 to 50). Majority (76.3%) of the partners perceived themselves as low risk for HIV acquisition. Similarly, most (93.8%) were objectively scored as low risk. However, nearly three quarters (72.7%) of partners who were objectively scored as high risk perceived themselves as being at low risk and all were men. The sensitivity and specificity of perceived risk for detecting the objectively measured risk was 27.3 and 76.5% respectively; area under ROC curve = 0.52; 95%CI (0.38, 0.66). The proportion of participants at high risk of HIV acquisition who perceived their risk as low was greater among those whose partners had detectable viral load compared to participants whose partners had undetectable viral load (PR = 0.51; 95%CI 0.29 to 0.90).

Conclusion

Incongruence between perceived and objectively measured risk of HIV acquisition does occur especially among individuals whose partners had a detectable viral load. PrEP counselling for serodiscordant couples should focus on explaining the consequence of detectable viral load in the HIV-positive partner on HIV transmission risk.
Literature
1.
go back to reference Caceres CF, Borquez A, Klausner JD, Baggaley R, Beyrer C. Implementation of pre-exposure prophylaxis for human immunodeficiency virus infection: progress and emerging issues in research and policy. J Int AIDS Soc. 2016;19(7(Suppl 6)):21108.PubMedPubMedCentral Caceres CF, Borquez A, Klausner JD, Baggaley R, Beyrer C. Implementation of pre-exposure prophylaxis for human immunodeficiency virus infection: progress and emerging issues in research and policy. J Int AIDS Soc. 2016;19(7(Suppl 6)):21108.PubMedPubMedCentral
2.
go back to reference Cowan FM, Delany-Moretlwe S, Sanders EJ, Mugo NR, Guedou FA, Alary M, et al. PrEP implementation research in Africa: what is new? J Int AIDS Soc. 2016;19(7(Suppl 6)):21101.PubMedPubMedCentral Cowan FM, Delany-Moretlwe S, Sanders EJ, Mugo NR, Guedou FA, Alary M, et al. PrEP implementation research in Africa: what is new? J Int AIDS Soc. 2016;19(7(Suppl 6)):21101.PubMedPubMedCentral
3.
go back to reference Plotzker R, Seekaew P, Jantarapakde J, Pengnonyang S, Trachunthong D, Linjongrat D, et al. Importance of risk perception: predictors of PrEP acceptance among Thai MSM and TG women at a community-based health service. JAIDS J Acquir Immune Defic Syndr. 2017;76(5):473–81.CrossRef Plotzker R, Seekaew P, Jantarapakde J, Pengnonyang S, Trachunthong D, Linjongrat D, et al. Importance of risk perception: predictors of PrEP acceptance among Thai MSM and TG women at a community-based health service. JAIDS J Acquir Immune Defic Syndr. 2017;76(5):473–81.CrossRef
4.
go back to reference Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet (London, England). 2007;369(9562):643–56.CrossRef Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet (London, England). 2007;369(9562):643–56.CrossRef
5.
go back to reference Eisingerich AB, Wheelock A, Gomez GB, Garnett GP, Dybul MR, Piot PK. Attitudes and acceptance of Oral and parenteral HIV Preexposure prophylaxis among potential user groups: a multinational study. PLoS One. 2012;7(1):e28238.CrossRef Eisingerich AB, Wheelock A, Gomez GB, Garnett GP, Dybul MR, Piot PK. Attitudes and acceptance of Oral and parenteral HIV Preexposure prophylaxis among potential user groups: a multinational study. PLoS One. 2012;7(1):e28238.CrossRef
6.
go back to reference Carroll JJ. Risk perception among HIV serodiscordant couples in East Africa taking oral PrEP for HIV prevention; 2015. Carroll JJ. Risk perception among HIV serodiscordant couples in East Africa taking oral PrEP for HIV prevention; 2015.
7.
go back to reference Pyra M, Brown ER, Haberer JE, Heffron R, Celum C, Bukusi EA, et al. Patterns of Oral PrEP adherence and HIV risk among eastern African women in HIV Serodiscordant partnerships. AIDS Behav. 2018;11:3718–25.CrossRef Pyra M, Brown ER, Haberer JE, Heffron R, Celum C, Bukusi EA, et al. Patterns of Oral PrEP adherence and HIV risk among eastern African women in HIV Serodiscordant partnerships. AIDS Behav. 2018;11:3718–25.CrossRef
8.
go back to reference Gray RH, Wawer MJ, Brookmeyer R, Sewankambo NK, Serwadda D, Wabwire-Mangen F, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet. 2001;357(9263):1149–53.CrossRef Gray RH, Wawer MJ, Brookmeyer R, Sewankambo NK, Serwadda D, Wabwire-Mangen F, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet. 2001;357(9263):1149–53.CrossRef
9.
go back to reference Lingappa JR, Hughes JP, Wang RS, Baeten JM, Celum C, Gray GE, et al. Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS One. 2010;5(9):e12598.CrossRef Lingappa JR, Hughes JP, Wang RS, Baeten JM, Celum C, Gray GE, et al. Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS One. 2010;5(9):e12598.CrossRef
10.
go back to reference Mermin J, Musinguzi J, Opio A, Kirungi W, Ekwaru JP, Hladik W, et al. Risk factors for recent HIV infection in Uganda. Jama. 2008;300(5):540–9.CrossRef Mermin J, Musinguzi J, Opio A, Kirungi W, Ekwaru JP, Hladik W, et al. Risk factors for recent HIV infection in Uganda. Jama. 2008;300(5):540–9.CrossRef
11.
go back to reference Castelnuovo B, Kiragga A, Musaazi J, Sempa J, Mubiru F, Wanyama J, et al. Outcomes in a cohort of patients started on antiretroviral treatment and followed up for a decade in an Urban Clinic in Uganda. PLoS One. 2015;10(12):e0142722.CrossRef Castelnuovo B, Kiragga A, Musaazi J, Sempa J, Mubiru F, Wanyama J, et al. Outcomes in a cohort of patients started on antiretroviral treatment and followed up for a decade in an Urban Clinic in Uganda. PLoS One. 2015;10(12):e0142722.CrossRef
12.
go back to reference Mujugira A, Celum C, Coombs RW, Campbell JD, Ndase P, Ronald A, et al. HIV Transmission Risk Persists During the First 6 Months of Antiretroviral Therapy. J Acquir Immune Defic Syndr (1999). 2016;72(5):579–84.CrossRef Mujugira A, Celum C, Coombs RW, Campbell JD, Ndase P, Ronald A, et al. HIV Transmission Risk Persists During the First 6 Months of Antiretroviral Therapy. J Acquir Immune Defic Syndr (1999). 2016;72(5):579–84.CrossRef
13.
go back to reference Irungu EM, Heffron R, Mugo N, Ngure K, Katabira E, Bulya N, et al. Use of a risk scoring tool to identify higher-risk HIV-1 serodiscordant couples for an antiretroviral-based HIV-1 prevention intervention. BMC Infect Dis. 2016;16(1):571.CrossRef Irungu EM, Heffron R, Mugo N, Ngure K, Katabira E, Bulya N, et al. Use of a risk scoring tool to identify higher-risk HIV-1 serodiscordant couples for an antiretroviral-based HIV-1 prevention intervention. BMC Infect Dis. 2016;16(1):571.CrossRef
14.
go back to reference Kahle EM, Hughes JP, Lingappa JR, John-Stewart G, Celum C, Nakku-Joloba E, et al. An empiric risk scoring tool for identifying high-risk heterosexual HIV-1 serodiscordant couples for targeted HIV-1 prevention. J Acquir Immune Defic Syndr (1999). 2013;62(3):339–47.CrossRef Kahle EM, Hughes JP, Lingappa JR, John-Stewart G, Celum C, Nakku-Joloba E, et al. An empiric risk scoring tool for identifying high-risk heterosexual HIV-1 serodiscordant couples for targeted HIV-1 prevention. J Acquir Immune Defic Syndr (1999). 2013;62(3):339–47.CrossRef
15.
go back to reference Evan Mulvihill SJ, Sun S, Hanashiro M, Morris S, Blumenthal J. Pre-exposure prophylaxis (PrEP) accessibility research and evaluation 2 (PrEPARE 2): HIV risk perception among men who have sex with men (MSM) University of California, USA Posters & Accepted Abstracts: Clin Pharmacol Biopharm. Las Vegas: 4th International Pharma & Clinical Pharmacy Congress; 2016 07–09, 2016. Evan Mulvihill SJ, Sun S, Hanashiro M, Morris S, Blumenthal J. Pre-exposure prophylaxis (PrEP) accessibility research and evaluation 2 (PrEPARE 2): HIV risk perception among men who have sex with men (MSM) University of California, USA Posters & Accepted Abstracts: Clin Pharmacol Biopharm. Las Vegas: 4th International Pharma & Clinical Pharmacy Congress; 2016 07–09, 2016.
16.
go back to reference Gallagher T, Link L, Ramos M, Bottger E, Aberg J, Daskalakis D. Self-perception of HIV risk and candidacy for pre-exposure prophylaxis among men who have sex with men testing for HIV at commercial sex venues in New York City. LGBT health. 2014;1(3):218–24.CrossRef Gallagher T, Link L, Ramos M, Bottger E, Aberg J, Daskalakis D. Self-perception of HIV risk and candidacy for pre-exposure prophylaxis among men who have sex with men testing for HIV at commercial sex venues in New York City. LGBT health. 2014;1(3):218–24.CrossRef
17.
go back to reference Xie L, Wu Y, Meng S, Hou J, Fu R, Zheng H, et al. Risk behavior not associated with self-perception of PrEP candidacy: implications for designing PrEP services. AIDS Behav. 2019;23(10):2784–94.PubMed Xie L, Wu Y, Meng S, Hou J, Fu R, Zheng H, et al. Risk behavior not associated with self-perception of PrEP candidacy: implications for designing PrEP services. AIDS Behav. 2019;23(10):2784–94.PubMed
18.
go back to reference Heffron R, Ngure K, Odoyo J, Bulya N, Tindimwebwa E, Hong T, et al. Pre-exposure prophylaxis for HIV-negative persons with partners living with HIV: uptake, use, and effectiveness in an open-label demonstration project in East Africa. Gates Open Res. 2017;1:3.CrossRef Heffron R, Ngure K, Odoyo J, Bulya N, Tindimwebwa E, Hong T, et al. Pre-exposure prophylaxis for HIV-negative persons with partners living with HIV: uptake, use, and effectiveness in an open-label demonstration project in East Africa. Gates Open Res. 2017;1:3.CrossRef
19.
go back to reference Charan J, Biswas T. How to calculate sample size for different study designs in medical research? Indian J Psychol Med. 2013;35(2):121.CrossRef Charan J, Biswas T. How to calculate sample size for different study designs in medical research? Indian J Psychol Med. 2013;35(2):121.CrossRef
20.
go back to reference Toren KG, Buskin SE, Dombrowski JC, Cassels SL, Golden MR. Time from HIV diagnosis to viral load suppression: 2007-2013. Sex Transm Dis. 2016;43(1):34–40.CrossRef Toren KG, Buskin SE, Dombrowski JC, Cassels SL, Golden MR. Time from HIV diagnosis to viral load suppression: 2007-2013. Sex Transm Dis. 2016;43(1):34–40.CrossRef
22.
go back to reference Castelnuovo B, Kiragga A, Mubiru F, Kambugu A, Kamya M, Reynolds SJ. First-line antiretroviral therapy durability in a 10-year cohort of naïve adults started on treatment in Uganda. J Int AIDS Soc. 2016;19(1):20773.CrossRef Castelnuovo B, Kiragga A, Mubiru F, Kambugu A, Kamya M, Reynolds SJ. First-line antiretroviral therapy durability in a 10-year cohort of naïve adults started on treatment in Uganda. J Int AIDS Soc. 2016;19(1):20773.CrossRef
23.
go back to reference Castelnuovo B, Mubiru F, Kiragga AN, Musomba R, Mbabazi O, Gonza P, et al. Antiretroviral treatment long-term (ALT) cohort: a prospective cohort of 10 years of ART-experienced patients in Uganda. BMJ Open. 2018;8(2):e015490.CrossRef Castelnuovo B, Mubiru F, Kiragga AN, Musomba R, Mbabazi O, Gonza P, et al. Antiretroviral treatment long-term (ALT) cohort: a prospective cohort of 10 years of ART-experienced patients in Uganda. BMJ Open. 2018;8(2):e015490.CrossRef
24.
go back to reference Carroll JJ, Heffron R, Mugo N, Ngure K, Ndase P, Asiimwe S, et al. Perceived risk among human immunodeficiency virus Serodiscordant couples in East Africa taking Oral pre-exposure prophylaxis. Sex Transm Dis. 2016;43(8):471–5.CrossRef Carroll JJ, Heffron R, Mugo N, Ngure K, Ndase P, Asiimwe S, et al. Perceived risk among human immunodeficiency virus Serodiscordant couples in East Africa taking Oral pre-exposure prophylaxis. Sex Transm Dis. 2016;43(8):471–5.CrossRef
25.
go back to reference Stringer EM, Sinkala M, Kumwenda R, Chapman V, Mwale A, Vermund SH, et al. Personal risk perception, HIV knowledge and risk avoidance behavior, and their relationships to actual HIV serostatus in an urban African obstetric population. J Acquir Immune Defic Syndr (1999). 2004;35(1):60.CrossRef Stringer EM, Sinkala M, Kumwenda R, Chapman V, Mwale A, Vermund SH, et al. Personal risk perception, HIV knowledge and risk avoidance behavior, and their relationships to actual HIV serostatus in an urban African obstetric population. J Acquir Immune Defic Syndr (1999). 2004;35(1):60.CrossRef
26.
go back to reference Corneli AL, McKenna K, Headley J, Ahmed K, Odhiambo J, Skhosana J, et al. A descriptive analysis of perceptions of HIV risk and worry about acquiring HIV among FEM-PrEP participants who seroconverted in Bondo, Kenya, and Pretoria, South Africa. J Int AIDS Soc. 2014;17:19152.CrossRef Corneli AL, McKenna K, Headley J, Ahmed K, Odhiambo J, Skhosana J, et al. A descriptive analysis of perceptions of HIV risk and worry about acquiring HIV among FEM-PrEP participants who seroconverted in Bondo, Kenya, and Pretoria, South Africa. J Int AIDS Soc. 2014;17:19152.CrossRef
27.
go back to reference Oltedal S, Moen B-E, Klempe H, Rundmo T. Explaining risk perception: an evaluation of cultural theory. Trondheim. 2004;85(1–33):86. Oltedal S, Moen B-E, Klempe H, Rundmo T. Explaining risk perception: an evaluation of cultural theory. Trondheim. 2004;85(1–33):86.
28.
go back to reference Corneli A, Wang M, Agot K, Ahmed K, Lombaard J, Van Damme L, et al. Perception of HIV risk and adherence to a daily, investigational pill for HIV prevention in FEM-PrEP. J Acquir Immune Defic Syndr. 2014;67(5):555–63.CrossRef Corneli A, Wang M, Agot K, Ahmed K, Lombaard J, Van Damme L, et al. Perception of HIV risk and adherence to a daily, investigational pill for HIV prevention in FEM-PrEP. J Acquir Immune Defic Syndr. 2014;67(5):555–63.CrossRef
29.
go back to reference Brenner H, Gefeller O. Variation of sensitivity, specificity, likelihood ratios and predictive values with disease prevalence. Stat Med. 1997;16(9):981–91.CrossRef Brenner H, Gefeller O. Variation of sensitivity, specificity, likelihood ratios and predictive values with disease prevalence. Stat Med. 1997;16(9):981–91.CrossRef
30.
go back to reference Corneli AL, Deese J, Wang M, Taylor D, Ahmed K, Agot K, et al. FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis. J Acquir Immune Defic Syndr (1999). 2014;66(3):324.CrossRef Corneli AL, Deese J, Wang M, Taylor D, Ahmed K, Agot K, et al. FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis. J Acquir Immune Defic Syndr (1999). 2014;66(3):324.CrossRef
31.
go back to reference Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509–18.CrossRef Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509–18.CrossRef
Metadata
Title
Perceived risk versus objectively measured risk of HIV acquisition: a cross-sectional study among HIV-negative individuals in Serodiscordant partnerships with clients attending an Urban Clinic in Uganda
Authors
Lillian Tugume
Timothy Ronald Muwonge
Edith Nakku Joloba
John Bosco Isunju
Flavia Matovu Kiweewa
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2019
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-019-7929-0

Other articles of this Issue 1/2019

BMC Public Health 1/2019 Go to the issue